(Yicai) May 14 -- Kexing Biopharm, a Chinese maker of recombinant protein medicines, said Peruvian regulators have green lighted its new cancer treatment five months earlier than expected following approvals from the European Union and the United Kingdom last year.

Peru’s General Directorate of Medicines, Supplies and Drugs approved Apexelsin just two months after receiving the application materials, the Jinan-based firm announced today.

Apexelsin, which was developed in collaboration with Haichang Biotech, is an Albumin-bound Paclitaxel, a class of cancer drugs that treat metastatic breast and pancreatic cancer, as well as non-small cell lung cancer.

The drug received EU approval at the end of July 2024 and the UK go-ahead in October. Kexing said it has already completed preparations for shipping to several European countries.

Global sales of Albumin-bound Paclitaxel drugs stood at about USD2.597 billion in 2023, according to data from Hengrui Pharmaceutical. The drugs sells for much more overseas than they do in the Chinese market, highlighting the strong potential for worldwide sales.

Editor: Tom Litting